Wedbush Issues Optimistic Forecast for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at Wedbush increased their Q4 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Monday, November 3rd. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.05. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ FY2029 earnings at $1.94 EPS.

Several other analysts also recently commented on BCRX. JMP Securities increased their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Zacks Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald lifted their target price on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Barclays cut their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

BioCryst Pharmaceuticals Trading Down 2.0%

NASDAQ BCRX opened at $7.03 on Thursday. The firm has a market capitalization of $1.48 billion, a P/E ratio of -39.05 and a beta of 1.09. The business has a fifty day simple moving average of $7.47 and a 200 day simple moving average of $8.67. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The firm had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. The firm’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.07) EPS. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Headlands Technologies LLC bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $32,000. Family Legacy Financial Solutions LLC bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth $72,000. New Age Alpha Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at $62,000. Allspring Global Investments Holdings LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter valued at $79,000. Finally, Farther Finance Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 8,109 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the sale, the director directly owned 65,352 shares of the company’s stock, valued at $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.